NCT04697719View on ClinicalTrials.gov

Body Weight, Aspirin Dose and Pro-resolving Mediators

PHASE4CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

November 4, 2021

Primary Completion Date

January 29, 2025

Study Completion Date

January 29, 2025

Conditions
Body Weight
Interventions
DRUG

Aspirin 81mg

81mg oral capsule

DRUG

Aspirin 325mg

325mg oral capsule

Trial Locations (1)

10016

NYU Langone Health, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT04697719 - Body Weight, Aspirin Dose and Pro-resolving Mediators | Biotech Hunter | Biotech Hunter